Business Context and Reporting Period
Pavmed Inc. (PAVM), an emerging growth company, filed this Form 8-K on January 5, 2021, to report the entry into a material definitive agreement and related equity offering. The company is headquartered in New York, New York, and its securities trade on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Details
- Offering Size: 6,000,000 shares of common stock.
- Purchase Price: $2.24 per share.
- Gross Proceeds: $13,440,000.
- Estimated Net Proceeds: Approximately $12,400,000 after deducting placement agent fees and estimated expenses.
- Placement Agent Fee: 7% of aggregate gross proceeds.
- Expense Reimbursement Cap: $15,000 for out-of-pocket accountable expenses.
- Expected Closing Date: On or about January 8, 2021.
The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
Material Changes and Transaction Structure
The company entered into a Placement Agency Agreement with Maxim Group LLC on a reasonable best efforts basis. Simultaneously, subscription agreements were executed with investors. The offering price of $2.24 per share exceeds the average Nasdaq Official Closing Price for the five trading days immediately preceding the signing. The transaction is conducted pursuant to an existing shelf registration statement on Form S-3 (Registration No. 333-248709) declared effective on September 17, 2020.
Outlook, Risks, and Contingencies
The closing of the offering is subject to customary closing conditions. The company has agreed to indemnify the placement agent and investors against certain liabilities under the Securities Act of 1933. The filing notes that representations and warranties in the agreements were made solely for the benefit of the parties and for risk allocation purposes, and may not reflect the company's current factual status outside the context of the agreement.
Key Facts for Investor Verification
- Verify the actual closing date and final net proceeds once the transaction settles.
- Confirm the dilution impact of the 6,000,000 new shares on existing shareholders.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) and Subscription Agreement (Exhibit 10.1) for specific covenants and conditions.
- Check subsequent filings for the use of proceeds and updated liquidity position.